Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomography
- PMID: 17164474
- DOI: 10.1124/jpet.106.114884
Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomography
Abstract
The occupancy by lorazepam of the benzodiazepine binding site of rat brain GABA(A) receptors was compared when measured using either in vivo binding of [(3)H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) in terminal studies or [(11)C]flumazenil binding in anesthetized animals assessed using a small animal positron emission tomography (PET) scanner (micro-PET). In addition, as a bridging study, lorazepam occupancy was measured using [(3)H]flumazenil in vivo binding in rats anesthetized and dosed under micro-PET conditions. Plasma lorazepam concentrations were also determined, and for each occupancy method, the concentration required to produce 50% occupancy (EC(50)) was calculated because this parameter is independent of the route of lorazepam administration. For the in vivo binding assay, lorazepam was dosed orally (0.1-10 mg/kg), whereas for the micro-PET study, lorazepam was given via the i.v. route as a low dose (0.75 mg/kg bolus) and then a high dose (0.5 mg/kg bolus then 0.2 mg/ml infusion). The lorazepam plasma EC(50) in the [(11)C]flumazenil micro-PET study was 96 ng/ml [95% confidence intervals (CIs) = 74-124 ng/ml], which was very similar to the [(3)H]flumazenil micro-PET simulation study (94 ng/ml; 95% CI = 63-139 ng/ml), which in turn was comparable with the [(3)H]flumazenil in vivo binding study (134 ng/ml; 95% CI = 119-151 ng/ml). These data clearly show that despite the differences in dosing (i.v. in anesthetized versus orally in conscious rats) and detection (in vivo dynamic PET images versus ex vivo measurements in filtered and washed brain homogenates), [(11)C]flumazenil micro-PET produces results similar to [(3)H]flumazenil in vivo binding.
Similar articles
-
The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.Br J Pharmacol. 2009 Jul;157(5):796-803. doi: 10.1111/j.1476-5381.2009.00216.x. Epub 2009 Apr 30. Br J Pharmacol. 2009. PMID: 19422390 Free PMC article.
-
Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans.J Pharmacol Exp Ther. 2010 Jan;332(1):17-25. doi: 10.1124/jpet.109.157909. Epub 2009 Sep 24. J Pharmacol Exp Ther. 2010. PMID: 19779131
-
Comparison of in vivo and ex vivo [3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors.Neuropharmacology. 2006 Jul;51(1):168-72. doi: 10.1016/j.neuropharm.2006.03.020. Epub 2006 May 11. Neuropharmacology. 2006. PMID: 16697018
-
Flumazenil: US clinical pharmacology studies.Eur J Anaesthesiol Suppl. 1988;2:81-95. Eur J Anaesthesiol Suppl. 1988. PMID: 2842144 Review.
-
Ethyl 8-fluoro-5-[11C]methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate.2008 Apr 28 [updated 2008 Jun 10]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2008 Apr 28 [updated 2008 Jun 10]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641752 Free Books & Documents. Review.
Cited by
-
Novel discriminative stimulus effects of TPA023B, subtype-selective gamma-aminobutyric-acid(A)/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023.Pharmacol Biochem Behav. 2008 Jul;90(1):65-73. doi: 10.1016/j.pbb.2008.02.019. Epub 2008 Feb 26. Pharmacol Biochem Behav. 2008. PMID: 18395780 Free PMC article.
-
Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain.EJNMMI Res. 2017 Dec;7(1):17. doi: 10.1186/s13550-017-0265-4. Epub 2017 Feb 22. EJNMMI Res. 2017. PMID: 28229437 Free PMC article.
-
COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics).J Med Toxicol. 2023 Jan;19(1):26-36. doi: 10.1007/s13181-022-00918-y. Epub 2022 Dec 16. J Med Toxicol. 2023. PMID: 36525217 Free PMC article. Review.
-
The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.Br J Pharmacol. 2009 Jul;157(5):796-803. doi: 10.1111/j.1476-5381.2009.00216.x. Epub 2009 Apr 30. Br J Pharmacol. 2009. PMID: 19422390 Free PMC article.
-
Direct Incorporation of [11C]CO2 into Asymmetric [11C]Carbonates.J Chem. 2018 Dec 10;2018:7641304. doi: 10.1155/2018/7641304. J Chem. 2018. PMID: 34079623 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources